Long-term safety and efficacy of intranasal ciclesonide in adult and adolescent patients with perennial allergic rhinitis

Annals of Allergy, Asthma and Immunology

Volumn 99, Issue 1, 2007, Pages 69-76

  Chervinsky, Paul ^a,f   Kunjibettu, Sudeesha ^b   Miller, David L ^c   Prenner, Bruce M ^d   Raphael, Gordon ^e   Hall, Nancy ^b   Shah, Tushar ^b  

^a Northeast Medical Research Associates Inc   (United States)

^b Nycomed US   (United States)

^c Allerg and Clin Immunol Assoc   (United States)

^d Allergy Associates Medical Group Inc   (United States)

^e Environmental Information Association   (United States)

^f Northeast Medical Research Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CICLESONIDE; HYDROCORTISONE; PLACEBO;

ADOLESCENT; ADULT; AGED; ARTICLE; BRONCHITIS; CATARACT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; ENT EXAMINATION; EPISTAXIS; EYE IRRITATION; FEMALE; HEADACHE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; INFLUENZA; INTRAOCULAR PRESSURE; LABORATORY TEST; LENS CAPSULE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NASAL DISCOMFORT; NOSE DISEASE; NOSE SEPTUM PERFORATION; NOSE ULCER; PERENNIAL RHINITIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SORE THROAT; SYMPTOMATOLOGY; TACHYPHYLAXIS; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VISUAL ACUITY; VITAL SIGN;

EID: 34447581139     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60624-2     Document Type: Article

References (23)

1. Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol. 2001;108(suppl):S2-S8.
2. Stempel DA, Woolf R. The cost of treating allergic rhinitis. Curr Allergy Asthma Rep. 2002;2:223-230.
3. HealthStar Communications, Inc., in partnership with Schulman, Ronca and Bucuvalas, Inc. Allergies in America: A Landmark Survey of Nasal Allergy Sufferers: Executive Summary. Florham Park, NJ: Altana Pharma Inc; 2006.
4. Derebery J, Boyle J, Droar J. Patient perspectives: AR and medication [abstract]. Otolaryngol Head Neck Surg. 2006;135(suppl):P96.
5. Bousquet J, Van Cauwenberge P, Khaltaev N; ARIA Workshop Group, World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108(suppl 5):S147-S334.
6. Naclerio RM, Boyle J, Droar J. AR: patient perspectives on INS [abstract]. Otolaryngol Head Neck Surg. 2006;135(suppl):P169. Abstract R184.
7. Moller C, Ahlstrom H, Henricson KA, Malmqvist LA, Akerlund A, Hildebrand H. Safety of nasal budesonide in the longterm treatment of children with perennial rhinitis. Clin Exp Allergy. 2003;33:816-822.
8. Klossek JM, Laliberte F, Laliberte MF, Mounedji N, Bousquet J. Local safety of intranasal triamcinolone acetonide: clinical and histological aspects of nasal mucosa in the long-term treatment of perennial allergic rhinitis. Rhinology. 2001;39:17-22.
9. Mandl M, Nolop K, Lutsky BN; 194-079 Study Group. Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. Ann Allergy Asthma Immunol. 1997;79:370-378.
10. Synnerstad B, Lindqvist N. A clinical comparison of intranasal budesonide with beclomethasone dipropionate for perennial non-allergic rhinitis: a 12 month study. Br J Clin Pract. 1996;50:363-366.
11. Nave R, Fisher R, Zech K. In vitro metabolism of ciclesonide in human lung and liver precision-cut tissue slices. Biopharm Drug Dispos. 2006;27:197-207.
12. Nave R, Meyer W, Fuhst R, Zech K. Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide. Pulm Pharmacol Ther. 2005;18:390-396.
13. Wingertzahn M, Sato H, Nave R et al. Esterases involved in the metabolism of ciclesonide (CIC) in human nasal epithelial cells (HNEC) [abstract]. J Allergy Clin Immunol. 2006;117(suppl):S167. Abstract 650.
14. Wingertzahn M, Nonaka R, Mochizuki T, Sato H, Kondo S. Reversibility of desisobutyryl-ciclesonide conversion to fatty acid conjugates [abstract]. J Allergy Clin Immunol. 2006;117(suppl):S167. Abstract 652.
15. Ratner P, Wingertzahn M, van Bavel J, et al. Effectiveness of ciclesonide nasal spray in the treatment of seasonal allergic rhinitis J Allergy Clin Immunol. In press.
16. Meltzer E, Kunjibettu S, Hall N, Berger W, LaForce C. Efficacy and safety of ciclesonide (CIC) for treatment of perennial allergic rhinitis (PAR) [abstract]. J Allergy Clin Immunol. 2006;117(suppl):S259. Abstract 1004.
17. Nave R, Wingertzahn MA, Brookman S, Kaida S, Matsunaga T. Safety, tolerability, and exposure of ciclesonide nasal spray in healthy and asymptomatic subjects with seasonal allergic rhinitis. J Clin Pharmacol. 2006;46:461-467.
18. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. Available at: www.wma.net/e/policy/b3.htm. Accessed May 2, 2006.
19. Chylack LT Jr., Wolfe JK, Singer DM, et al; The Longitudinal Study of Cataract Study Group. The Lens Opacities Classification System III. Arch Ophthalmol. 1993;111:831-836.
20. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy. 1991;21:77-83.
21. Ratner P, Wingertzahn M, van Bavel J, et al. Efficacy and safety of ciclesonide nasal spray for the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol. 2006;118:1142-1148.
22. Salib RJ, Howarth PH. Safety and tolerability profiles of intranasal antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis. Drug Saf. 2003;26:863-893.
23. Waddell AN, Patel SK, Toma AG, Maw AR. Intranasal steroid sprays in the treatment of rhinitis: is one better than another? J Laryngol Otol. 2003;117:843-845.